Dr. Ravi on Ongoing Investigation of PSMA-targeted Therapies in mCRPC


In Partnership With:

Praful K. Ravi, MB, BChir, MRCP, discusses ongoing and future clinical trials investigating the use of prostate-specific membrane antigen-targeted therapies in metastatic castration-resistant prostate cancer.

Praful K. Ravi, MB, BChir, MRCP, medical oncologist, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses ongoing and future clinical trials investigating the use of prostate-specific membrane antigen (PSMA)-targeted therapies in metastatic castration-resistant prostate cancer (mCRPC).

The targeted radioligand Lutetium 177 (177Lu) PSMA-617 (177Lu-PSMA-617) was previously studied in the phase 3 VISION trial (NCT03511664), Ravi begins. The trial evaluated PSMA-positive patients who were previously treated with at least one androgen receptor (AR) inhibitor and 1 or 2 taxane regimens. Results from the trial demonstrated that 177Lu-PSMA-617 prolonged both median radiographic progression-free survival (rPFS) and overall survival when added to standard-of-care (SOC) treatment options in mCRPC.

There are 2 main trials currently evaluating the use of this agent in earlier stages of mCRPC, Ravi continues. The phase 3 PSMAfore trial (NCT04689828) is comparing the effect of 177Lu-PSMA-617 vs changing AR-directed therapy (ARDT), on the risk of radiographic progression or death, he explains. The trial population consists of patients with mCRPC or metastatic hormone-sensitive prostate cancer (mHSPC) who were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen. A recent press release stated that the trial had met its primary end point of a clinically meaningful improvement in rPFS, but initial data are still forthcoming, Ravi notes.

Additionally, the phase 3 PSMAddition trial (NCT04720157) aims to investigate the efficacy and safety of 177Lu-PSMA-617 in combination with SOC androgen deprivation therapy (ADT) plus ARDT compared with ARDT and ADT alone in patients with mHSPC, Ravi says.

Aside from these large-scale efforts, several smaller trials have been designed to investigate 177Lu-PSMA-617 in combination with PARP inhibitors or immunotherapies, Ravi says. Future research will likely continue the development of these novel combination regimens and focus on implementing PSMA-targeted strategies in earlier stages of disease, he concludes.

Related Videos
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH